Bristol-Myers Squibb Launches an Online Resource for Patients with Chronic Myeloid Leukaemia in 15 European Countries

Paris (ots/PRNewswire) -

My CML Life Online Resource Centre Empowers and Guides Patients
with CML

Through Different Stages of Their Journey

Bristol-Myers Squibb Company today announced the introduction of
"My CML Life", a disease awareness website for patients with chronic
myeloid leukaemia (CML). In recognition of the need to raise
awareness of this rare cancer, Bristol-Myers Squibb launched the "My
CML Life" website to provide patients in Europe with
easy-to-understand medical information and tools that offer support
through various stages of their journey with CML.

"We are excited to bring this resource to patients and their
caregivers in Europe," said Estelle Vester-Blockland, Executive
Medical Director Oncology for Bristol-Myers Squibb. "Bristol-Myers
Squibb will be providing this resource to patients in 15 countries
across Europe, offering them support to manage and cope with their
disease, and empower them to have a more informed dialogue with their
doctor".

The educational content featured on the "My CML Life" website was
developed by Bristol-Myers Squibb in close consultation with their
advisory committee. Comprising CML medical experts who verified the
scientific information and patient advocates who ensured that the
patients' needs were taken into account, the committee worked in
collaboration with BMS to provide insight and feedback on content,
development and structure.

"We were looking to take a patient-oriented approach to explain to
the patient, in a friendly way, the most important things when living
with CML," said Dr Javier López Jiménez, head of the clinical
department at the Hospital Ramón y Cajal in Madrid and member of the
"My CML Life" website advisory committee. "I think that the website
can be a big help for the patient because, when the patient is quiet
at home, he can look at it and know better the side effects and how
to manage them".

The "My CML Life" website provides patients with information on
CML symptoms and diagnosis, an overview of available treatment
options, and what to expect at treatment initiation and monitoring.
The site also offers easy-to-use practical tools and services for
patients. These include key questions for patients to ask their
doctor during follow-up visits and treatment, adverse event diaries
to help monitor their progress, and disease management tips to
support them in their daily journey in CML. Links to other useful
resources, including a list of patient advocacy groups, are also
available for patients to access information from leading CML
experts.

For more information about "My CML Life"

The website has recently been launched in Spain and France and
will be rolled out in 13 other countries across Europe including
Austria, Belgium, Denmark, Greece, Ireland, the Netherlands, Norway,
Poland, Portugal, Romania, Sweden, Switzerland and the U.K.

Please visit http://www.mycmllife.eu/fr and
http://www.mycmllife.eu/es

About Chronic Myeloid Leukaemia

CML is a slow-growing type of leukaemia in which the body produces
an uncontrolled number of abnormal white blood cells.[1] CML accounts
for 15% of all leukaemias.[2] In Europe, the incidence is estimated
at 10 to 15 cases per 1,000,000 people.[3]

CML occurs when pieces of two different chromosomes (9 and 22)
break off and attach to each other. The new chromosome is called the
Philadelphia-positive chromosome, which contains an abnormal gene
called BCR-ABL that signals cells to make too many white blood cells.
There is no known cause for the genetic change that causes CML.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines that
help patients prevail over serious diseases.

References:

1.Macmillan Cancer Support. Leukaemia Overview. Available at: http
://www.macmillan.org.uk/Cancerinformation/Cancertypes/Leukaemia/Leuka
emiaoverview.aspx . Last accessed April 2012.

2. National Comprehensive Cancer Network (NCCN). Chronic
Myelogenous Leukemia - Clinical Practice Guidelines in Oncology -
v.1.2007.

3. Baccarani, M et al. Annals Oncol. 2012:23 (Suppl
7):vii72-vii77.

ots Originaltext: Bristol-Myers Squibb GmbH & Co.KG aA
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Media Contact: Astrid Harmel, +33-1-58-83-61-49,
astrid.harmel@bms.com